PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet , one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's...
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
HONG KONG, Sept. 3, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data...
Chip Wade Outfits Perch Luxury Treehouses with SKYWORTH's Lifestyle TV Lineup, Led by Its Canvas Art® TV
SKYWORTH is Debuting a New Canvas Art ® TV Line at the Show CYPRESS, Calif., Sept. 3, 2026 /PRNewswire/ -- SKYWORTH, a global leader in advanced display technology, partnered with Emmy-winning designer and TV host Chip Wade to outfit his Perch...
Armstrong Intelligent Solutions Drive Energy-Efficient Building Design
Armstrong Fluid Technology Highlights 'Intelligent Design and Energy-Efficient Technology' at BEX Asia 2026 SINGAPORE, Sept. 2, 2026 /PRNewswire/ -- Armstrong Fluid Technology, a global leader in intelligent, energy-saving fluid-flow and...
Exploring Singapore with AI! Singapore Tourism Board and Mafengwo Jointly Launch "Singapore AI Inspiration Lab" to Unlock the Many Facets of the Lion City for Seniors, Families, and New Workforce Entrants
BEIJING, Aug. 25, 2026 /PRNewswire/ -- On August 23, the Singapore Tourism Board and Mafengwo, [China's largest travel community], joined forces once again to launch the "Singapore AI Inspiration Lab – Lion City Adventure • More Fun, More You"...
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis...
Ariel Green Pays Technology Performance Insurance Claim for Plastic Recycling Facility, Demonstrating Protection for Clean Energy Projects
Claim Proves How Technology Performance Insurance Protects Clean Energy Investments and Supports Continued Operations LONDON, July 15, 2026 /PRNewswire/ -- Ariel Green today announced the payment of a Technology Performance Insurance (TPI) claim for...
2026 IB Results: A Testament to Holistic Education As 208 YCYW Students Secure Outstanding Global Results
HONG KONG, July 8, 2026 /PRNewswire/ -- The results for the International Baccalaureate Diploma Programme (IBDP) were recently released, and the Class of 2026 of YCYW Education Network (YCYW) has once again achieved outstanding results. This year, A...
Nota AI Has Two MoE Quantization Papers Accepted at ICML 2026 Workshop, Demonstrating Global Competitiveness in Large-Scale AI Optimization
Two papers on MoE-specific quantization algorithms accepted at a workshop held in conjunction with ICML 2026 Recognition follows Nota AI's overall win at the NVIDIA Nemotron Hackathon Strengthening core optimization technologies to make large-scale...
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026...